When was enGene founded?

enGene was founded in 1999 and raised its 1st funding round 2 years after it was founded.

Where is enGene located?

enGene is headquartered in Saint laurent, Canada. It is registered at 4868 RUE LEVY, SUITE 220,SAINT-LAURENT,H4R 2P1,QC.

How many employees does enGene have?

As of Apr 30, 2026, the latest employee count at enGene is 144.

Is enGene a funded company?

enGene is a funded company, having raised a total of $54M across 9 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on Aug 15, 2001.

When was the latest funding round of enGene?

enGene's latest funding was a $***** Post IPO round on Oct 25, 2024, with participation from 7 investors.

Where does enGene rank among its competitors?

enGene ranks 50th amongst 2423 active competitors, of which 628 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of enGene?

enGene's top competitors include Alnylam, Spark Therapeutics and Synthego. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

enGene - 2026 Company Profile, Funding, Competitors & Financials

enGene is a public company based in Saint laurent (Canada), founded in 1999. It operates as a Developer of oral non-viral gene therapy platform. enGene has raised $54M in funding from investors like Hercules Capital, Forbion and Lumira Ventures. The company has 2423 active competitors, including 628 funded and 454 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Synthego.

Company Details

EnGene is developing a non-viral gene therapy platform for the delivery of nucleic acid payloads to mucosal tissues. Its flagship platform DDX is a derived chitosan platform delivers DNA and various forms of RNA to broad tissue and disease applications. It has also developed a gut-optimized gene delivery formulation, Gene Pill for Short Bowel Syndrome (SBS). Gene Pill enables the oral delivery of DNA encoding a long-acting GLP-2 analog directly to GIT.

Website: engene.com
Phone Number: +1 **********
Registered Address: 4868 RUE LEVY, SUITE 220,SAINT-LAURENT,H4R 2P1,QC

Key Metrics

Founded Year

1999

Location

Saint laurent, Canada

Stage

Public

Total Funding

$54M in 9 rounds

Latest Funding Round

Post IPO, Oct 25, 2024, $*****

Investors

Hercules Capital & 16 more

Ranked

50^th among 2423 active competitors

Employee Count

144 as on Apr 30, 2026

Similar Companies

Alnylam & 3257 more

Exit Details

Public

View enGene's full profile

enGene is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Engene Holdings Inc. CIN: 1980845 , United States, Active		-	-	-

enGene got listed on Nov 01, 2023.

Click here to take a look at enGene's IPO in detail

enGene has raised a total funding of $54M over 9 rounds. Its first funding round was on Aug 15, 2001. Its latest funding round was a Post IPO round on Oct 25, 2024 for $*****. 7 investors participated in its latest round. enGene has 17 institutional investors.

Here is the list of recent funding rounds of enGene:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 25, 2024	2399180	Post IPO	2801399	3359965	2826549	8729113
Feb 14, 2024	6560367	Post IPO	5661508	3241008	2130161	7625318
Dec 26, 2023	7527837	Convertible Debt	7036561	3104982	Hercules Capital	3547415

Access funding benchmarks and valuations. Sign up today!

View details of enGene's funding rounds and investors

enGene's employee count trend

enGene has 144 employees as of Apr 26. Here is enGene's employee count trend over the years:

Uncover enGene's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of enGene include Alnylam, Spark Therapeutics and Synthego. Here is the list of Top 10 competitors of enGene, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
4th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, MassChallenge & 19 others	71/100
5th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
6th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
7th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
8th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	Healthcap, F-Prime Capital & 9 others	69/100
9th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	Fidelity Investments, T. Rowe Price & 9 others	69/100
10th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, EDBI & 16 others	68/100
50th	enGene 1999, Saint laurent (Canada), Public	Developer of oral non-viral gene therapy platform	$54M	Deep Track Capital, Venrock & 15 others	62/100